ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

World Health Organization approves updated cholera vaccine to combat surge in cases

The World Health Organization has approved a new version of a cholera vaccine that could help address a surge in cases that has depleted the global vaccine stockpile.

The World Health Organization has approved a version of a widely used cholera vaccine that could help address a surge in cases that has depleted the global vaccine stockpile and left poorer countries scrambling to contain epidemics.

WHO authorized the vaccine, made by EuBiologics, which also makes the formulation now used, last week. The new version, called Euvichol-S, is a simplified formula that uses fewer ingredients, is cheaper, and can be made more quickly than the old version.

The vaccine was shown to be help preventing the diarrheal disease in late stage research conducted in Nepal.

WORST CHOLERA OUTBREAK IN 2 DECADES SWEEPS THROUGH ZAMBIA, KILLING MORE THAN 400

WHO’s approval means donor agencies like the vaccines alliance Gavi and UNICEF can now buy it for poorer countries. Leila Pakkala, director of UNICEF’s supply division, said in a statement that the agency will be able to boost supplies by more than 25%.

Gavi estimated there could be about 50 million doses for the global stockpile this year, compared with 38 million last year.

Dr. Derrick Sim of Gavi called WHO’s authorization "a lifeline for vulnerable communities around the world."

More is still needed, however: Since January, 14 countries affected by cholera outbreaks have requested 79 million doses. In January, the U.N. agency said the global vaccine stockpile was "entirely depleted" until the beginning of March. As of this week, WHO said there were 2.3 million doses available.

Cholera is an acute diarrhea disease caused by a bacteria typically spread via contaminated food or water. It is mostly seen in areas that have poor sanitation and lack access to clean water. While most people infected with cholera don't experience symptoms, those with severe cases need quick treatment with intravenous fluids and antibiotics. If left untreated, cholera kills about a quarter to half of people infected.

Since last January, WHO has reported more than 824,000 cholera infections, including 5,900 deaths worldwide, with the highest numbers of cases reported in the Middle East and Africa. The U.N. agency said warming temperatures that allow the cholera bacteria to live longer, have also worsened outbreaks and led to the highest death rates in a decade.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.